As of July 1st 2023, olaparib is reimbursed in a 6th indication for the adjuvant treatment of adults with high-risk HER2-negative early breast cancer and a germline BRCA1 or BRCA2 mutation. Olaparib is the first and only targeted treatment option that is approved for these patients.1 Patients are eligible after completion of treatment with an anthracycline and/or taxane in the (neo)-adjuvant setting. Reimbursement was granted based on the positive results of the OlympiA trial, in which adjuvant olaparib reduced the risk of invasive disease or death by 42% as compared to placebo. In addition, adjuvant olaparib significantly improved the overall survival, with a 32% risk reduction as compared to placebo. Finally, olaparib has a manageable safety profile.2,3 This new reimbursement adds on to the five previously reimbursed indications of olaparib in ovarian cancer, locally advanced or metastatic breast cancer, prostate cancer and pancreatic cancer.1
REFERENCES
Top
